DAPA-HFrEF
An International, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic HFrEF
- Stadium
- klaar
- Middel
- dapagliflozin
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 17 maart 2017
- Last Patient In
- 4 juni 2018
- Last Patient Last Visit
- 17 juli 2019
National Lead
prof. dr. R.A. de Boer
Cardioloog
Studiedirecteur
